Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Sarah Holstein on Lenalidomide Maintenance Updates

September 1st 2015

Sarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.

FDA Grants Elotuzumab Priority Review in Multiple Myeloma

September 1st 2015

The FDA has granted elotuzumab (Empliciti) a priority review for use in combination therapy in pretreated patients with multiple myeloma.

Second Study Proves Daratumumab's Efficacy in Multiple Myeloma

August 27th 2015

Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.

Takeda Completes Second Ixazomib Myeloma Filing

August 21st 2015

The European Medicines Agency has accepted a marketing authorization application for ixazomib in combination with lenalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma.

Dr. Voorhees on the Future Treatment Paradigm for Myeloma

August 11th 2015

Peter Voorhees, MD, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

Two FDA Approvals, BRAF/MEK Breakthrough Status in NSCLC, and More

August 3rd 2015

FDA Expands Carfilzomib's Myeloma Approval

July 24th 2015

The FDA has broadened the approval of carfilzomib to include patients with relapsed multiple myeloma who have received at least one prior therapy.

Carfilzomib ENDEAVOR Data Submitted to FDA for Myeloma Approval

July 23rd 2015

A supplemental new drug application has been submitted for carfilzomib (Kyprolis) in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More

July 19th 2015

Immunomodulatory Agents in Multiple Myeloma

July 17th 2015

Monoclonal Antibodies in Multiple Myeloma

July 17th 2015

Role of Carfilzomib in Multiple Myeloma

July 17th 2015

Pomalidomide and Carfilzomib in Refractory Multiple Myeloma

July 17th 2015

Panobinostat in Relapsed/Refractory Multiple Myeloma

July 17th 2015

Resistance to Multiple Myeloma Maintenance Therapy

July 17th 2015

Multiple Myeloma: Considerations in Stem Cell Transplantation

July 17th 2015

High-Risk Versus Low-Risk Multiple Myeloma

July 17th 2015

Treatment Approaches in Newly Diagnosed Multiple Myeloma

July 17th 2015

FDA Approval Sought for Ixazomib in Relapsed/Refractory Myeloma

July 14th 2015

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

Long-Term Data Further Define Benefit of Lenalidomide Maintenance in Myeloma

July 7th 2015

Philip McCarthy, MD, explains the significance of the updated CALGB 100104 study results.